Cancer immunotherapy aims at eliciting an immune response directed against tumor
antigens to help fight off residual tumor cells and thereby improve survival and quality of life …

Md. Selim Ahmed et al• Dendritic cell-based tumor vaccine 114 http://www. ecevr. org/
http://dx. doi. org/10.7774/cevr. 2014.3. 2.113 of 7.1%[4]. Though not firmly established, the …

Despite recent attempts to take advantage of dendritic cell (DC)-based vaccines for cancer
immunotherapy, the results of clinical studies have been disappointing. This is mainly as a …

Although different types of therapeutic vaccines against established cancerous lesions in
various indications have been developed since the 1990s, their clinical benefit is still very …

If one envisions dendritic cells (DCs) as nature's adjuvant, then it is easy to predict that they
would be advantageous for cancer immunotherapy. Advances in culture processes that …

During the last decade use of dendritic cells (DC) has moved from murine and in vitro
studies to clinical trials as adjuvant in cancer immunotherapy. Here they function as delivery …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APCs), and
are capable of stimulating naive T cells and driving primary immune responses. Due to this …

The potential for the immune system to target hematological malignancies is demonstrated
in the allogeneic transplant setting, where durable responses can be achieved. However …

ABSTRACT B and T lymphocytes are the effectors of specific immunity. However, their
function is critically dependent on dendritic cells (DC). DC are professional antigen …

Among the many cancer therapeutics being presently developed, antigen-specific
immunotherapy is considered a particularly promising approach. Active immunotherapy or …